<DOC>
	<DOCNO>NCT00849069</DOCNO>
	<brief_summary>The purpose study evaluate safety , reactogenicity immunogenicity GSK2231395A candidate vaccine adult elderly adult chronic obstructive pulmonary disease . Subjects vaccinate 3 time interval respectively 2 10 month .</brief_summary>
	<brief_title>Study Assess Safety New GSK Biologicals ' GSK2231395A Candidate Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol enrol study . A male female , 40 80 year age , inclusive , time consent . Written inform consent obtain subject . Subject confirm history chronic obstructive pulmonary disease exacerbation , include multiple exacerbation 24 month prior Screening Subject baseline chest Xray obtain untreated/off systemic corticosteroid least 30 day duration Subject able perform baseline pre postbronchodilator pulmonary function test untreated/off systemic corticosteroid least 30 day duration participate pulmonary rehabilitation program . If subject female , childbearing potential , agree use acceptable contraception become pregnant duration study . Is establish screen pulmonary function test mild chronic obstructive pulmonary disease Is establish screen PFT clinical history severe chronic obstructive pulmonary disease Is diagnose respiratory disorder chronic obstructive pulmonary disease Has primary diagnosis asthma . Is prescribed/receiving systemic antibiotic last 30 day . Is prescribed/receiving systemic corticosteroid last 30 day . Has chronic administration immunosuppressant immunemodifying drug within 6 month prior first vaccine dose . Is undergoing , plan undergo , undergone last 6 month pulmonary rehabilitation program . Has undergone , plan undergo , lung transplantation and/or lung volume reduction . Has chest xray indicate acute pulmonary disease require therapy might interfere study , CAP , tuberculosis , lung cancer Has pneumonia within 3 month prior first vaccination . Is receive regular longterm oxygen therapy . Has know diagnosis α1 antitrypsin deficiency . Has know suspect hypersensitivity/reaction component candidate vaccine , comparator vaccine ( Twinrix® Adult ingredient ) , and/or bronchodilator use study procedure . Has previously vaccinate Hepatitis A and/or B . As portion subject randomize receive Twinrix® Adult comparator , important subject qualify receive Twinrix® Adult . Is use investigational nonregistered product ( drug vaccine ) study vaccine , within 30 day precede first dose study vaccine , plan use study period , participation another pharmaceutical/vaccine study . Has administer , plan administration , vaccine foreseen study protocol within 30 day first dose vaccine . Has administration immunoglobulins and/or blood product within 3 month prior first vaccination . Has confirm suspect immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . Has significant disease , opinion investigator , likely interfere study and/or likely cause death within study duration . Has acute cardiac insufficiency . Has inflammatory process know chronic active infection ( e.g . Hepatitis B , Hepatitis C ) . Has past current malignancy lymphoproliferative disorder . Has clinically significant hematological biochemical abnormality per judgment investigator . Has acute disease time vaccination . Is pregnant lactate female . Is female plan become pregnant planning discontinue contraceptive precaution . Has , opinion investigator , evidence alcohol drug abuse . Has condition principal investigator judge may interfere study finding .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Streptococcus pneumoniae</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Non-typable Haemophilus influenza</keyword>
	<keyword>Adults Elderly Adults</keyword>
</DOC>